Track topics on Twitter Track topics that are important to you
NewsThe licensing agreement for the HD20 trastuzumab biosimilar gives Cipla Ltd. exclusive rights to distribute and market the drug in selected emerging markets.
NewsMylan's NDA for generic versions of Lantus and Lantus SoloSTAR, co-developed with Biocon, is under active review by the FDA.
Singapore, December 14, 2018 / B3C newswire / -- Prestige BioPharma (“Prestige”) announced today that it has reached a licensing agreement with
Held annually alongside Biotech Showcase and OneMed Forum, the JP Morgan conference is one of the largest and most informative healthcare symposiums in the industry. BioSim will be meeting throughout the conference to update suppliers and interested parties on state of their research and development program. BioSim’s ACTH Gelatin Depot 80 IU/mL ...
Indiviorâs patent litigation with Dr. Reddyâs over Suboxone film continues after the company announced its preliminary injunction will stay in place.
SummaryCipla Ltd Cipla is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients APIs. It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, malaria, cancer, ne...
Indivior prevails in attempt to stall US launch of Dr. Reddy's Suboxone generic https://www.firstwordpharma.com/node/1611017 $INDV
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter (OTC) store-brand equivalent of Prilosec® OTC (omeprazole delayed-release) Tablets, 20 mg, in the United States market a...
SummaryCadila Pharmaceuticals Ltd Cadila develops, manufactures and distributes pharmaceutical products. The company's products include active pharmaceutical ingredients API and pharmaceutical formulations. It offers products in the form of capsules, tablets, orals, soft and hard gelatin capsules, and liquid solutions. The company's business operations include contract research, contract manufactu...
The US Court of Appeals is clearing the way for generics competitors to enter the market. The court has lifted an injunction on Dr Reddy’s Suboxone (buprenorphine/naloxone) generic and upheld a decision to invalidate Johnson & Johnson’s (J&J) patent on its blockbuster prostate cancer drug Zytiga (abiraterone).
In November 2018, Indian generics maker Glenmark Pharmaceuticals (Glenmark) announced the approval of generics for the treatment of multiple sclerosis (MS) and pneumonia.
Lupin has received 22 observations across three facilities at its Mandideep campus, which the company says are only âprocedural in natureâ.
SummaryLupin Ltd Lupin focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients APIs. The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastrointestinal, antiinfectives, nonsteroidal antiinflammatory drugs NSAIDs, antiTB and cephalosporins. It underta...
The US Court of Appeals for the Federal Circuit removed the injunction against Dr. Reddyâs, which prevented the company from selling its Suboxone generic.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton (chlorthalidone) Tablets, approved by the U.S. Food and Drug Administration (USFDA). ...
SummaryDr. Reddy's Laboratories Ltd Dr. Reddy's is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company's generic products are used for the treatment of conditions such as gastrointestinal disorders, oncology, cardiovascular diseases, pain management, Central Nervous System, cancer, pain, ...
A U.S. federal appeals court threw out a preliminary injunction that had blocked the generics maker from launching a copy of Indivior's opioid treatment.